The Short-Form 12 (SF-12) mental component score (MCS) and Short-Form 6-Dimensional (SF-6D) demonstrated good validity in assessing the quality of life (QoL) associated with atopic dermatitis (AD), according to study results published in the Journal of Investigative Dermatology.

A total of 602 of 2893 patients included in the study met the criteria for AD (prevalence, 7.39%; 95% CI, 5.81-8.97). At baseline, mean patient age was 52.0±16.3 years. The weighted mean Patient-Oriented Scoring Atopic Dermatitis (PO-SCORAD) was 27.5 (95% CI, 25.7-29.3), the Patient-Oriented Eczema Measure (POEM) was 7.5 (95% CI, 6.8-8.1), SF-12 MCS was 45.9 (95% CI, 45.0-46.9), physical-component score (PCS) was 53.0 (95% CI, 52.8- 53.3), SF-6D was 0.69 (95% CI, 0.68-0.71), and Dermatology Life Quality Index (DLQI) was 4.9 (4.2-5.5).

Strong correlations were found between the SF-12 MCS and SF-6D with regard to convergent validity, whereas moderate inverse correlations were found with the POEM, PO-SCORAD, PO-SCORAD-itch, PO-SCORAD-sleep, and numerical rating scale of pain (P <.0001 for all). Good discriminant validity was found for the MCS and SF-6D.

There were weak correlations and poor discriminant validity between the SF-12 PCS and AD severity assessments. The DLQI demonstrated better convergent and discriminant validity than the SF-12; however, both the SF-12 and DLQI had good internal consistency (Cronbach’s alpha: 0.89 and 0.94). The researchers found differential item functioning for items in the SF-12 and DLQI.

Related Articles

For moderate and severe AD, the optimal thresholds for SF-12 MCS were 46.6 (sensitivity, 60.2%; specificity, 62.6%) and 42.1 (sensitivity, 70.6%; specificity, 56.7%), respectively. For SF-6D, the optimal thresholds for moderate and severe AD were 0.67 (sensitivity, 67.3%; specificity, 66.7%) and 0.61 (sensitivity, 69.2%; specificity, 52.8%), respectively.

Study limitations include the lack of clinician-confirmed AD classification, as well as the lack of responsiveness, test-retest reliability or content validity assessments.

Based on their findings, the researchers suggest that both the “SF-12 MCS and SF-6D may be useful for the assessment of the burden of AD in clinical trials and practice.”

Disclosure: This study was sponsored by Sanofi Genzyme and Regeneron. Multiple authors disclosed affiliations with pharmaceutical companies. See the reference for complete disclosure information.

Follow @DermAdvisor

Reference

Silverberg JI, Gelfand JM, Margolis DJ, et al. Validation and interpretation of short form 12 and comparison with dermatology life quality index in atopic dermatitis in adults [published online April 19, 2019]. J Invest Dermatol. doi:10.1016/j.jid.2019.03.1152